These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 39223018)

  • 1. [Application of ARHGAP8 in Predicting the Efficacy of Neoadjuvant Chemotherapy for Locally Advanced Mid-Low Rectal Cancer].
    Xi YN; Xue J; Wu XL; Qu M; Sun GY; Han L; Guo F; Zhang CZ; Wang YF; Liang WZ
    Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2024 Aug; 46(4):528-538. PubMed ID: 39223018
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical Analysis of the Efficacy and Safety of Different Neoadjuvant Strategies in the Treatment of Locally Advanced Rectal Cancer.
    Chen W; Wang W; Huang S; Zhou L; Wang G; Chen W
    Cancer Invest; 2024 Aug; 42(7):661-670. PubMed ID: 39037150
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Relationship between Expression of Runt-related Transcription Factor 3 and Enhancer of zeste Homolog 2 Proteins and Sensitivity to Neoadjuvant Chemotherapy in Locally Advanced Rectal Cancer].
    Yuan ZL; Wu XL; Qu M; Xue J; Han L; Sun GY
    Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2021 Dec; 43(6):856-864. PubMed ID: 34980322
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Analysis on efficacy and safety of total neoadjuvant therapy in patients with locally advanced rectal cancer with high risk factors].
    Ouyang GL; Meng WJ; Shu P; Deng XB; Wu B; Jiang D; Zhuang H; Shen YL; Zhou ZG; Wang ZQ; Wang X
    Zhonghua Wei Chang Wai Ke Za Zhi; 2019 Apr; 22(4):349-356. PubMed ID: 31054549
    [No Abstract]   [Full Text] [Related]  

  • 5. Korean Society of Coloproctology (KSCP) trial of cONsolidation Chemotherapy for Locally advanced mid or low rectal cancer after neoadjUvant concurrent chemoraDiothErapy: a multicenter, randomized controlled trial (KONCLUDE).
    Kim CW; Kang BM; Kim IY; Kim JY; Park SJ; Park WC; Bae KB; Bae BN; Baek SK; Baik SH; Son GM; Lee YS; Lee SH
    BMC Cancer; 2018 May; 18(1):538. PubMed ID: 29739356
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Feasibility Study of Neoadjuvant XELOX Without Radiotherapy for Locally Advanced Lower Rectal Cancer.
    Ueki T; Manabe T; Inoue S; Ienaga J; Yamanaka N; Egami T; Ishikawa M; Konomi H; Ikubo A; Nagayoshi K; Nakamura M; Tanaka M
    Anticancer Res; 2016 Feb; 36(2):741-7. PubMed ID: 26851033
    [TBL] [Abstract][Full Text] [Related]  

  • 7. ACRNaCT trial protocol: efficacy of adjuvant chemotherapy in patients with clinical T3b/T4, N+ rectal Cancer undergoing Neoadjuvant Chemoradiotherapy: a pathology-oriented, prospective, multicenter, randomized, open-label, parallel group clinical trial.
    Li Q; Luo D; Zhu J; Yang L; Liu Q; Ma Y; Liang L; Cai S; Zhang Z; Li X;
    BMC Cancer; 2019 Nov; 19(1):1117. PubMed ID: 31729964
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Validation of a genome-based model for adjusting radiotherapy dose (GARD) in patients with locally advanced rectal cancer.
    Xia H; Li Z; Lin Y; Lin Y; Zeng L; Xu B; Yao Q; Zheng R
    Sci Rep; 2024 Sep; 14(1):21572. PubMed ID: 39284851
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Short-term outcome of programmed cell death protein1 (PD-1) antibody combined with total neoadjuvant chemoradiotherapy in the treatment of locally advanced middle-low rectal cancer with high risk factors].
    Li YJ; Zhang L; Dong QS; Cai Y; Zhang YZ; Wang L; Yao YF; Zhang XY; Li ZW; Li YH; Sun YS; Wang WH; Wu AW
    Zhonghua Wei Chang Wai Ke Za Zhi; 2021 Nov; 24(11):998-1007. PubMed ID: 34823301
    [No Abstract]   [Full Text] [Related]  

  • 10. Impact of adjuvant chemotherapy after neoadjuvant radio- or radiochemotherapy for patients with locally advanced rectal cancer.
    Lichthardt S; Zenorini L; Wagner J; Baur J; Kerscher A; Matthes N; Kastner C; Pelz J; Kunzmann V; Germer CT; Wiegering A
    J Cancer Res Clin Oncol; 2017 Nov; 143(11):2363-2373. PubMed ID: 28756493
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nomogram basing pre-treatment parameters predicting early response for locally advanced rectal cancer with neoadjuvant chemotherapy alone: a subgroup efficacy analysis of FOWARC study.
    Zhang J; Cai Y; Hu H; Lan P; Wang L; Huang M; Kang L; Wu X; Wang H; Ling J; Xiao J; Wang J; Deng Y
    Oncotarget; 2016 Jan; 7(4):5053-62. PubMed ID: 26646794
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [The safety and efficacy of radical surgery after modified total neoadjuvant therapy for locally advanced rectal cancer].
    Zhang L; Yu L; Wu YL; Zhang QQ; Shen SH; Li DD; Fang H; Yang L; Zhang HZ
    Zhonghua Zhong Liu Za Zhi; 2020 Jun; 42(6):501-506. PubMed ID: 32575948
    [No Abstract]   [Full Text] [Related]  

  • 13. Analyses of predictive factors for pathological complete remission in neoadjuvant therapy for locally advanced rectal cancer.
    Yang J; Ling X; Tang W; Hu D; Zhou H; Yin G
    J BUON; 2019; 24(1):77-83. PubMed ID: 30941954
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Identification of a biomarker profile associated with resistance to neoadjuvant chemoradiation therapy in rectal cancer.
    Garcia-Aguilar J; Chen Z; Smith DD; Li W; Madoff RD; Cataldo P; Marcet J; Pastor C
    Ann Surg; 2011 Sep; 254(3):486-92; discussion 492-3. PubMed ID: 21865946
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Neoadjuvant chemotherapy with modified FOLFOXIRI for locally advanced rectal cancer to transform effectively EMVI and MRF from positive to negative: results of a long-term single center phase 2 clinical trial.
    Zhang W; Zhou H; Jiang J; Zhu Y; Zou S; Jiang L; Tang Y; Liang J; Sun Y; Jiang Z; Qu W; Li Y; Zhou A
    BMC Cancer; 2023 Jun; 23(1):592. PubMed ID: 37370032
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [A case of pathological complete response with neoadjuvant XELOX chemotherapy for locally advanced rectal cancer].
    Kitahara T; Takemasa I; Inoue A; Osawa H; Miyo M; Mokutani Y; Ogawa H; Naito A; Hamabe A; Hiraki M; Munakata K; Uemura M; Nishimura J; Hata T; Mizushima T; Yamamoto H; Doki Y; Mori M
    Gan To Kagaku Ryoho; 2014 Nov; 41(12):1569-71. PubMed ID: 25731255
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Construction of a model based on multipoint full-layer puncture biopsy for predicting pathological complete response after neoadjuvant therapy for locally advanced rectal cancer].
    Jin Y; Zhai ZW; Sun LT; Xia PD; Hu H; Jiang CQ; Zhao BC; Qu H; Qian Q; Dai Y; Yao HW; Wang ZJ; Han JG
    Zhonghua Wei Chang Wai Ke Za Zhi; 2024 Apr; 27(4):403-411. PubMed ID: 38644246
    [No Abstract]   [Full Text] [Related]  

  • 18. [Surgical management of patients with pathologic complete response in the primary tumor after neoadjuvant chemotherapy for rectal cancer].
    Cui J; Yang L; Guo L; Shao Y; Li N; Zhang H
    Zhonghua Zhong Liu Za Zhi; 2015 Jun; 37(6):456-60. PubMed ID: 26463151
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Impact of Chronic Kidney Disease in Patients With Locally Advanced Rectal Cancer Treated With Neoadjuvant Chemoradiation.
    Dudani S; Marginean H; Gotfrit J; Tang PA; Monzon JG; Dennis K; Kennecke HF; Powell ED; Babak S; Cheung WY; Vickers MM
    Dis Colon Rectum; 2021 Dec; 64(12):1471-1478. PubMed ID: 34657078
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Controversies and progress in adjuvant chemotherapy for patients with locally advanced rectal cancer receiving neoadjuvant chemoradiotherapy].
    Li XX; Li QG
    Zhonghua Wei Chang Wai Ke Za Zhi; 2019 Jun; 22(6):594-596. PubMed ID: 31238639
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.